Introduction of REGN-COV2 Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6 Code History

Introduction of Sarilumab into Central Vein, Percutaneous Approach, New Technology Group 5 Code History

Introduction of Non-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy into Central Vein, Percutaneous Approach, New Technology Group 10 Code History

Introduction of Bamlanivimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6 Code History

Introduction of Other New Technology Therapeutic Substance into Central Vein, Percutaneous Approach, New Technology Group 5 Code History

Introduction of Other New Technology Therapeutic Substance into Central Vein, Percutaneous Approach, New Technology Group 3 Code History

Introduction of Etesevimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6 Code History

Introduction of Remdesivir Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 5 Code History

Introduction of Atezolizumab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 6 Code History

Introduction of Zanidatamab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 10 Code History